|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:alsoKnownAs
|
gptkb:PF-07321332
|
|
gptkbp:approvalYear
|
2021
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:ATCCode
|
J05AE10
|
|
gptkbp:brand
|
gptkb:Nirmatrelvir
|
|
gptkbp:CASNumber
|
gptkb:1369773-39-6
|
|
gptkbp:combines
|
gptkb:Ritonavir
|
|
gptkbp:component
|
gptkb:Paxlovid
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:hasInChIKey
|
GGXKCSFZOLZRSR-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C23H32F3N5O4
|
|
gptkbp:hasSMILES
|
CC1(C)C2CN(C(=O)C(NC(=O)C(F)(F)F)C(C)C)C(=O)N2C(C1)C(=O)NC3CCCCC3
|
|
gptkbp:hasUNII
|
QHU4A4K8FJ
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
1369773-39-6
|
|
gptkbp:indication
|
gptkb:COVID-19
|
|
gptkbp:KEGGID
|
D12372
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
SARS-CoV-2 main protease inhibitor
|
|
gptkbp:molecularWeight
|
499.5 g/mol
|
|
gptkbp:pregnancyCategory
|
Not assigned (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL4297599
gptkb:DB16335
155903259
103083463
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:bfsParent
|
gptkb:sacubitril
|
|
gptkbp:bfsLayer
|
6
|